文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

18F-Fluciclovine PET对前列腺癌生化复发患者管理的影响:FALCON试验结果

Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-02-14

FALCON试验在英国6个中心纳入104例首次生化复发的前列腺癌患者,行18F-Fluciclovine PET/CT后56%检出病灶,64%患者管理方案改变(其中65%为主要改变)。在18F-Fluciclovine指导挽救治疗者中PSA反应率高于未指导者(88% vs 72%)。

要点

  • 18F-Fluciclovine PET/CT在56%生化复发患者中检出病灶,检出率随PSA升高而增加。
  • 64%患者扫描后管理方案改变,其中65%为主要改变(如挽救治疗改为观察等待)。
  • 18F-Fluciclovine指导挽救治疗者PSA反应率88%,未指导者72%。

核心结论

  • 18F-Fluciclovine PET/CT能在多数生化复发前列腺癌患者中定位复发灶,并常导致主要管理方案改变。

研究设计与样本

  • FALCON为在英国6个中心开展的前瞻性研究,纳入104例首次生化复发且接受过根治性治疗的前列腺癌患者。
  • 患者按标准化流程行18F-Fluciclovine PET/CT,临床医生记录扫描前后的管理计划并分类为主要改变或其他改变。

主要发现

  • 104例患者中58例(56%)检出病灶,中位PSA为0.79 ng/mL。
  • PSA≤1 ng/mL时约1/3扫描阳性,PSA>2.0 ng/mL时93%扫描阳性。
  • 66例(64%)患者扫描后管理计划改变,其中阳性结果后改变占80%。
  • 66例改变中43例(65%)为主要改变:挽救或系统治疗改为观察等待16例(24%),挽救治疗改为系统治疗16例(24%),其他治疗模式改变11例(17%)。
  • 其余23例(35%)为计划内调整,其中22例(33%)为调整近距离放疗/放疗以包含18F-Fluciclovine引导的推量。

关键数值与推荐

  • 18F-Fluciclovine指导挽救治疗者PSA反应率为15/17(88%),未指导者为28/39(72%)。

临床怎么用

  • 对生化复发前列腺癌患者可考虑行18F-Fluciclovine PET/CT以定位复发灶并指导挽救治疗决策。
  • 根据PET/CT结果可调整放疗靶区(如包含引导推量)或避免无效的挽救治疗。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Early and accurate localization of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The present study, 18F-Fluciclovine PET/CT in biochemicAL reCurrence Of Prostate caNcer (FALCON; NCT02578940), aimed to evaluate the effect of 18F-fluciclovine on management of men with BCR of prostate cancer. METHODS AND MATERIALS: Men with a first episode of BCR after curative-intent primary therapy were enrolled at 6 UK sites. Patients underwent 18F-fluciclovine positron emission tomography/computed tomography (PET/CT) according to standardized procedures. Clinicians documented management plans before and after scanning, recording changes to treatment modality as major and changes within a modality as other. The primary outcome measure was record of a revised management plan postscan. Secondary endpoints were evaluation of optimal prostate specific antigen (PSA) threshold for detection, salvage treatment outcome assessment based on 18F-fluciclovine-involvement, and safety. RESULTS: 18F-Fluciclovine was well tolerated in the 104 scanned patients (median PSA = 0.79 ng/mL). Lesions were detected in 58 out of 104 (56%) patients. Detection was broadly proportional to PSA level; ≤1 ng/mL, 1 out of 3 of scans were positive, and 93% scans were positive at PSA >2.0 ng/mL. Sixty-six (64%) patients had a postscan management change (80% after a positive result). Major changes (43 out of 66; 65%) were salvage or systemic therapy to watchful waiting (16 out of 66; 24%); salvage therapy to systemic therapy (16 out of 66; 24%); and alternative changes to treatment modality (11 out of 66, 17%). The remaining 23 out of 66 (35%) management changes were modifications of the prescan plan: most (22 out of 66; 33%) were adjustments to planned brachytherapy/radiation therapy to include a 18F-fluciclovine-guided boost. Where 18F-fluciclovine guided salvage therapy, the PSA response rate was higher than when 18F-fluciclovine was not involved (15 out of 17 [88%] vs 28 out of 39 [72%]). CONCLUSIONS: 18F-Fluciclovine PET/CT located recurrence in the majority of men with BCR, frequently resulting in major management plan changes. Incorporating 18F-fluciclovine PET/CT into treatment planning may optimize targeting of recurrence sites and avoid futile salvage therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Scarsbrook AF, Bottomley D, Teoh EJ, et al. Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32068113. doi:10.1016/j.ijrobp.2020.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。